期刊文献+

兔眼玻璃体腔注射抗血管内皮生长因子单克隆抗体Bevacizumab的毒性观察 被引量:1

Toxicity observation of intravireal injection of bevacizumab in rabbit eyes
原文传递
导出
摘要 目的观察不同剂量的抗血管内皮生长因子单克隆抗体Bevacizumab玻璃体腔注射后对兔眼角膜、房角、视网膜组织结构和功能的影响。方法24只健康新西兰大白兔分成3组,每组兔眼右眼分别注射Bevacizumab 1.25、2.50、5.00mg;左眼为对照眼,注射相同体积的0.9%生理盐水。注射药物前后裂隙灯显微镜及直接检眼镜检查眼前段和眼底,监测眼压。注药前以及注药后1、4、8周行闪光视网膜电图(ERG)检查。8周时行角膜内皮计数后,摘除眼球行光学显微镜及透射电子显微镜检查。结果3组兔眼注射药物前后各时间点眼压、角膜内皮计数、ERG的a、b波振幅差异无统计学意义(P〉0.05)。光学显微镜检查,3组兔眼角膜、房角、视网膜结构无明显变化。透射电子显微镜检查,视网膜超微结构亦无明显变化。结论玻璃体腔内注射1.25~5.00mg Bevacizumab对正常兔眼组织没有明显毒性。 Objective To observe the effects of structure and function of cornea, chamber angle and retina of varying doses of Bevacizumab which was injected intravitreally in rabbits. Methods Twenty-four New Zealand albino rabbits were divided into three groups randomly, the right eyes in three groups received intravitreal injection Avastin at dose 1.25 mg, 2.5 mg and 5 mg respectively as experimental eye, the left eyes accepted intravitreal injection 0. 9 % normal saline at the same volume as a control eye. The anterior segment of eye and ocular fundus were examined and intraocular pressure was measured by slit-lamp microscope and direct ophthalmoscope before and after injection. It was tested by Electroretinogram (ERG) before and after injection 1, 4, 8 weeks. At the 8th week, it carried out corneal endothelium counting; then enucleated eyes to observe by the light microscope and transmission electron microscope. Results No statistically significant difference regard to 10P,corneal endothelium counting, a- and b-waves of ERG at any stage of study in every group(P〉0.05). No obvious change at cornea, chamber angle, retinal structure and retinal ultrastructure in every group under light microscope. Conclusion This study indicated that there is no obvious toxicity of intravitreal injection with Avastin 1.25-5.0 mg in normal rabbit eyes.
出处 《中华眼底病杂志》 CAS CSCD 北大核心 2008年第3期189-192,共4页 Chinese Journal of Ocular Fundus Diseases
关键词 抗体 单克隆/毒性 视网膜/病理学 动物实验 BEVACIZUMAB Antibodies, monoclonal/toxicity Retina/pathology animal experimentation Bevacizumab
  • 引文网络
  • 相关文献

参考文献11

  • 1Yang JC, Haworth L,Sherry RM,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 2003,349: 427-434.
  • 2Spaide RF, Laud K, Fine HF, et al. Intravtreal bevacizumab treatment of ehoroidal neovaseularization secondary to age- related maeular degeneration. Retina, 2006, 26:383-390.
  • 3Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology, 2006,113 : 1695-1705.
  • 4Laud K, Spaide RF, Freund KB,et al, Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina, 2006,26 : 960 963.
  • 5Manzano RP,Peyman GA, Khan P,et al. Testing intravitreal toxicity of bevacizuma (Avastin). Retina, 2006,26 : 257-226.
  • 6Feiner L,Barr EE,Shui YB,et al. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina, 2006,26 : 882-888.
  • 7Luthra S,Narayanan R,Marques LE,et al. Evaluation of in vitro effects of bevaeizumab (Avastin)on retinal pigment epithelial, neurosensory retinal, and mierovaseular endothelial cells. Retina, 2006,26 : 512-518.
  • 8张远.药物代谢动力学//张远.药理学.2版.北京:北京大学医学出版社,2003:9-18.
  • 9李劲,杨红,胡正,杜蜀华.双氯芬酸钠兔眼玻璃体内注射对视网膜电图影响的研究[J].眼科研究,2001,19(1):26-28. 被引量:2
  • 10Maturi RK, Bleau LA, Wilson DL,et al. Electrophysiologic findings after intravitreal bevaeizumab (Avastin) treatment, Retina, 2006,26:270-274

二级参考文献8

  • 1Blumenkranz MS,Claflin A,HajekAS.Selection of therapeutic agents for intraocular proliferative disease.Cell cultureevaluation.Arch Ophthalmol,1984,102∶598
  • 2Glaser BM,Lemor M.In Retina.Vol 3.Mosby Year Book,1994∶2249
  • 3Packo KH.In Macular Surgery.Appleon & Lange,1994∶85
  • 4Chandler DB,Hida T,Sheta S,et al.Improvement in efficacy of corticosteroidtherapy in an animal model of proliferative vitreoretinopathy by pretreatment.Graefe’sArch Clin Exp Ophthalmol,1987,225∶259
  • 5Kahler CM,Kieselbach GF,Reinisch N,et al.Fibroblast growthpromotingactivity in proliferative vitreoretinopathy:antagonism by acetylsalicylic acid.Eur JPharmacol,1994,262∶261
  • 6Stern WH,Blumenkranz MS.Fluid-gas exchange after vitrectomy.Am J Ophthalmol,1983,96∶33
  • 7Kulkarni PS,Paterson CA.Diclofenac and prednisolone inhibit endotoxin-induceduveitis in rabbits.Exp Eye Res,1995,61∶767
  • 8谢雷克.双氯灭痛在眼科的研究进展[J].国外医学(眼科学分册),1997,21(4):207-211. 被引量:20

共引文献1

同被引文献25

  • 1Heilweil G,Komarowska I,Avery L, Goldstein M,Perlman I,Loewenstein A. Pharmacokinetics of bevacizumab after single intravitreal injection in rabbits [ J ]. Invest Ophthalmol Vis Sci, 2007,48 ( 1 ) :92.
  • 2Bakn S, Snyder M, Reid J, Pulido J, Singh RJ. Pharmacokinetics of intravitreal bevacizumab ( avastin ) [ J ]. Ophthalmology, 114 (5) :855-859.
  • 3Nomoto H, Kuno N, Kimura E, Hirooka K, Shimga F. Bevacizumab pharmacokineties admini-stered by eye-drops, subconjunctival injection and intravitrealinjection in rabbits[ J]. Invest Ophthalmol Vis Sci,2008,49(5) :1827-1832.
  • 4Csaky KG, Gordiyenko N, Rabena MG, Avery RL. Pharmacokinetics of mtravitreal bevacizumab in humans [ J ]. Invest Ophthalmol Vis Sci ,2007,48 ( 11 ) :4936-4946.
  • 5Krohne T, Eter N, Holz F, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans [ J ]. Am J Ophthalmol,2008,146 (4) :508-512.
  • 6Cousins SW, Csaky K. Analysis of potential toxicity following intravitreal injections of bevacizumab and pegaptanib in nonhuman primate eyes[J]. Invest Ophthalmol Vis Sci,2007,48( 1 ) : 22.
  • 7Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes[J]. Invest Ophthalmol Vis Sci,2007,48(4) :1773-1781.
  • 8Shahar J,Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, et al. Retinal electrophysiologic, morphologic and penetration studies following intravitreal injection of bevacizumab(avastin) [ J]. Invest Ophthalmol Vis Sci,2006,47 ( 9 ) : 2102-2109.
  • 9Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (avastin) [ J]. Retina,2006,26 ( 3 ) : 257-261.
  • 10Moreno-Paramo D, Perez-Reguera A, Meza-de Regil A, Meza-de Regil,Abraham M, Parrochia M, et al. Safety and tolerance of bevacizumab injection in rabbit anterior chamber [ J ]. Invest Ophthalmol Vis Sci,2006,47:3236.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部